PTC THERAPEUTICS, INC. Segments Disclosure
15. Segment and geographic information
The Company views its operations and manages its business in one operating segment: life science. The table below summarizes the significant expense categories for the life science segment regularly reviewed by the CODM for the years ended December 31, 2025, 2024, and 2023:
Years Ended December 31, | |||||||||
2025 | 2024 | 2023 | |||||||
Total revenues | $ | 1,730,655 | $ | 806,780 | $ | 937,822 | |||
Less: | |||||||||
Cost of product, collaboration and license sales | 28,427 | 26,901 | 27,404 | ||||||
Program spend | 201,706 | 211,230 | 258,705 | ||||||
Employee costs | 283,583 | 251,184 | 334,305 | ||||||
Manufacturing costs | 67,323 | 64,120 | 86,641 | ||||||
Administrative costs | 73,805 | 72,420 | 70,531 | ||||||
Occupancy costs | 29,561 | 34,913 | 42,085 | ||||||
Milestones | — | 65,000 | 30,000 | ||||||
Other segment items (a) | 363,606 | 444,307 | 714,755 | ||||||
Segment net income (loss) | $ | 682,644 | $ | (363,295) | $ | (626,604) | |||
Reconciliation of profit or loss | |||||||||
Adjustments and reconciling items | — | — | — | ||||||
Consolidated net income (loss) | $ | 682,644 | $ | (363,295) | $ | (626,604) | |||
| (a) | Other segment items includes the following: |
Years Ended December 31, | |||||||||
2025 | 2024 | 2023 | |||||||
Interest income | $ | (74,078) | $ | (47,314) | $ | (13,325) | |||
Interest expense | 226,308 | 214,307 | 142,505 | ||||||
Income tax expense (benefit) | 13,975 | 176 | (69,506) | ||||||
Depreciation | 14,196 | 14,924 | 13,947 | ||||||
Amortization | 24,742 | 60,738 | 222,635 | ||||||
All other (b) | 158,463 | 201,476 | 418,499 | ||||||
Total other segment items | $ | 363,606 | $ | 444,307 | $ | 714,755 | |||
| (b) | All other includes cost of goods sold, royalty, travel and entertainment, distribution costs, bad debt expense, finance costs, contract labor costs, stock compensation expense, change in the fair value of contingent consideration, and other expense. |
The following table presents financial information based on the geographic location of the facilities of the Company as of and for the years ended:
Year Ended December 31, 2025 | |||||||||
| United States | | Non-US | | Total | ||||
Total assets | $ | 2,525,035 | $ | 373,732 | $ | 2,898,767 | |||
Fixed assets, net | $ | 54,109 | $ | 1,262 | $ | 55,371 | |||
Revenue | $ | $ | 235,888 | $ | 1,730,655 | ||||
Year Ended December 31, 2024 | |||||||||
| United States | | Non-US | | Total | ||||
Total assets | $ | 1,343,234 | $ | 361,790 | $ | 1,705,024 | |||
Fixed assets, net | $ | 59,748 | $ | 1,222 | $ | 60,970 | |||
Revenue | $ | $ | 393,736 | $ | 806,780 | ||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 19, 2026 | Showing above |
| 2024 | Feb 27, 2025 | |
| 2023 | Feb 29, 2024 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.